Evidence map›Paper›PMID 35637978›Full record

ReviewAnnals of medicine and surgery (2012)2022

Safety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: A systematic review and meta-analysis.

Talal Almas, Faeez Muhammad, Laiba Siddiqui, Batool Shafi, Rabbia Gul, Rafiya Altaf, Zaeem Abbasi, Ghulam Mustafa, Arham Iqbal, Amatul Rehman Durdana and 3 more

Open access · diamondAbstract readReview
In one paragraph

Review in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Talal AlmasDepartment of Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Faeez MuhammadDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Laiba SiddiquiDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Batool ShafiDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Rabbia GulDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Rafiya AltafDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Zaeem AbbasiDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Ghulam MustafaDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Arham IqbalDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Amatul Rehman DurdanaDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Maham DilawarDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Adeena MusheerDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Kaneez FatimaDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Dow University of Health Sciences · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Many publications have compared various outcomes defining safety and efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and DOACs for its treatment effects over different BMI ranges. Methods: A systematic search was conducted from inception to May 2021 on PubMed, Scopus and Embase databases. The data was extracted and pooled using a random effects model. Our study consisted of patients being treated for VTE and AF, across different BMI categories. For the comparison of DOAC, risk ratios (RR) with 95% confidence intervals (CIs) were used, whilst for the second comparison between warfarin and DOACs odds ratios (OR) were used. Results: In our first comparison, 12 studies ( Conclusion: The risk of VTE reduces with an increasing BMI, hence there could be a possible obesity paradox in patients with anticoagulation therapy. In comparison to warfarin, DOACs proved to be the safer option by having a reduced risk of bleeding across all BMI categories.

Indexed as

BMI (Body mass index)DOAC (direct oral anticoagulants)EfficacySafetyWarfarin

Identifiers

PMID35637978
PMCPMC9142411
OpenAlexW4223889421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.